🔰 New Series: Awareness of #Interventional_Radiotherapy (#Brachytherapy)
Episode 2 — Cervical Cancer & HDR #Brachytherapy Boost after EBRT
The #EMBRACEII trial (1,482 patients, 49 centers) confirms that MR-guided adaptive brachytherapy remains essential for locally advanced cervical cancer.
✅ 93% local control (3 years)
✅ 94% pelvic control
✅ 82% overall survival (5 years)
✅ Reduced severe late toxicity vs EMBRACE I
📢 Modern radiotherapy + chemotherapy + image-guided brachytherapy = new standard of care.
#InterventionalRadiotherapy #CervicalCancer #RadiationOncology #ESTRO2025 #WomenHealth #CancerCare #ThisIsBrachytherapy
Kidney SABR on the front cover of @TheLancetOncol. A well-deserved recognition for @_ShankarSiva for his work and efforts over the past 10+ years.
https://t.co/07jeA1lQMb
🚨CAN-2409 + RT: not just delaying PSA failure, reducing residual tumor in the gland.🚨
@TheLancetOncol
👉Phase 3, double-blind RCT
🧑🤝🧑745 pts w/ int/high-risk localized #prostatecancer
⚖️EBRT + intraprostatic CAN-2409/valacyclovir vs placebo.
💉CAN-2409 is a replication-defective adenoviral HSV-tk gene therapy injected into the prostate.
💊Valacyclovir acts as the prodrug to drive local tumor-cell kill + immune priming
📉 DFS improved: HR 0.70; median NR vs 86.1 mo.
🔬 Key nuance: DFS included local failure by centrally reviewed positive prostate biopsy, protocol biopsy ~2 yrs post-EBRT.
🎯 At 22–26 mo: positive biopsies 20% vs 36%; pCR 80% vs 63%.
🛡️ No major toxicity penalty: grade ≥3 TEAEs 8% vs 7%; no treatment-related deaths.
🔑CAN-2409 may not just suppress biochemical recurrence, it may deepen local tumor eradication after RT.
@PCFnews@PCF_Science@urotoday@UrologyTimes
🔗https://t.co/GyvKotnfdK
🚨🚨 ASCO 2026 Final Results Randomized trial resected brain met Brachytherapy vs Post-Op SRS🚨
- Incredible Surg Bed Control with Brachy (↑↑OS as well)
- Surg bed recurrence 12% SRS vs 1% GammaTile
@jjnaylor02@TylerSbrt@VedangMurthy@piet_ost@DrAndrewLoblaw With that said, people thought neoadj ADT was critical before RT and it took decades to finally prove it likely adds almost no benefit and it really is the adjuvant component.
When outcomes already so good every percent matters…hard to prove each last percent.
¡Otro gran trabajo en #ESTRO2026! Compartimos los resultados a largo plazo de la braquiterapia HDR boost en cáncer de próstata (TC based vs TRUS). Datos robustos con más de 10 años de seguimiento medio que avalan un excelente control y supervivencia de los pacientes.
Fantastic long term data for HDR boost. Very interesting to see lower side effect profile for TRUS based over CT based planning. More confidence in contouring or greater certainty in needle positioning at time of treatment? @agomeziturriaga@KamravaMD
Join us at #ABSBrachy26 for the #judithstitt Plenary as Bryce Thomsen presents a Phase II randomized, blinded trial comparing AI‑assisted & manual contouring by new learners in ultrasound‑based #prostate HDR #brachy, with @AndrewFarach providing the discussant perspective.
@HimanshuNagarMD@TylerSbrt@piet_ost@DrStish Think remains possible. ASTRO 2025 PCSVI presentation by Dr Niazi showed lower late GI with HDR/EBRT vs MHRT - first time BT boost less AEs. I believe PRIME @VedangMurthy so far equal for SBRT and fractionated RT (although less with weekly SBRT). Curious to compare as mature
Yesterday, I presented the @GETUG_Unicancer PEACE 2 trial at #ESTRO26 on the role of pelvic RT in very high risk #prostatecancer pts (staged with conventional imaging).
Twittorial below
Key conclusion: pelvic RT did not improve clinical outcomes (cPFS, MFS, PCSS, OS)...
1/n